Table 3.
Subgroup analyses for the associations of polypharmacy with up‐to‐5‐year OS in older patients with CRC
| Variable | Total n | Cases, n (%) | HR (95% CI) a | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0–4 drugs | 5–7 drugs | ≥8 drugs | 0–4 drugs | 5–7 drugs | ≥8 drugs | 0–4 drugs | 5–7 drugs | ≥8 drugs | |
| Age, yr | |||||||||
| 65–74 | 848 | 491 | 313 | 209 (24.7) | 129 (26.3) | 99 (31.6) | Ref | 1.07 (0.84–1.37) | 1.32 (0.96–1.80) |
| ≥75 | 619 | 497 | 471 | 221 (35.7) | 197 (39.6) | 215 (45.7) | Ref | 1.05 (0.85–1.30) | 1.22 (0.97–1.54) |
| Sex | |||||||||
| Female | 549 | 435 | 350 | 166 (30.2) | 143 (32.9) | 144 (41.1) | Ref | 0.92 (0.71–1.19) | 1.27 (0.95–1.69) |
| Male | 918 | 553 | 434 | 264 (28.8) | 183 (33.1) | 170 (39.2) | Ref | 1.15 (0.93–1.41) | 1.16 (0.91–1.47) |
| Tumor location | |||||||||
| Colon | 926 | 616 | 546 | 290 (31.3) | 194 (31.5) | 218 (39.9) | Ref | 0.94 (0.77–1.14) | 1.23 (0.98–1.54) |
| Rectum | 541 | 372 | 238 | 140 (25.9) | 132 (35.5) | 96 (40.3) | Ref | 1.40 (1.07–1.83) | 1.36 (0.97–1.89) |
| Chemotherapy | |||||||||
| No chemotherapy | 841 | 628 | 558 | 200 (23.8) | 167 (26.6) | 205 (36.7) | Ref b | 0.87 (0.64–1.18) b | 1.17 (0.75–1.38) b |
| Chemotherapy | 624 | 360 | 225 | 229 (36.7) | 159 (44.2) | 108 (48.0) | Ref b | 1.38 (0.98–1.95) b | 1.42 (0.92–2.20) b |
| Tumor stage | |||||||||
| I and II | 812 | 568 | 465 | 144 (17.7) | 105 (18.5) | 130 (28.0) | Ref | 0.84 (0.64–1.11) | 1.02 (0.75–1.38) |
| III | 454 | 296 | 223 | 133 (29.3) | 120 (40.5) | 110 (49.3) | Ref | 1.22 (0.91–1.63) | 1.50 (1.09–2.08) |
| IV | 192 | 120 | 89 | 152 (79.2) | 99 (82.5) | 70 (78.7) | Ref | 1.06 (0.78–1.42) | 1.13 (0.79–1.62) |
| Functional status | |||||||||
| Excellent | 297 | 135 | 80 | 58 (19.5) | 36 (26.7) | 24 (30.0) | Ref | 1.34 (0.81–2.21) | 1.73 (0.93–3.23) |
| Fair | 423 | 261 | 202 | 118 (27.9) | 67 (25.7) | 74 (36.6) | Ref | 1.04 (0.73–1.49) | 1.33 (0.89–1.98) |
| Poor | 280 | 287 | 303 | 105 (37.5) | 122 (42.5) | 134 (44.2) | Ref | 1.23 (0.92–1.64) | 1.08 (0.79–1.49) |
Values in bold are statistically significant (p < .05).
a
Adjusted for age, sex, tumor stage, tumor location, year of CRC diagnosis, neoadjuvant/adjuvant chemotherapy, year of schooling, smoking status, body mass index, lifetime physical activity, lifetime alcohol consumption, red meat consumption, processed meat consumption, functional status, and comorbidity except stratifying factor.
b
Data are shown as OR (95% CI).
Abbreviations: CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio; OR, odds ratio.